Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $0.10 million for the quarter.
Abeona Therapeutics Stock Performance
NASDAQ:ABEO opened at $5.29 on Friday. The stock’s fifty day moving average is $5.53 and its 200 day moving average is $5.84. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.87. The firm has a market capitalization of $229.96 million, a PE ratio of -1.97 and a beta of 1.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.
Wall Street Analysts Forecast Growth
ABEO has been the topic of several recent research reports. Oppenheimer began coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. Finally, StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
- Five stocks we like better than Abeona Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Stock Market Upgrades: What Are They?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to trade penny stocks: A step-by-step guide
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
